JP5448462B2 - 改善されたバイオアベイラビリティーを有するクルクミンのリン脂質複合体 - Google Patents
改善されたバイオアベイラビリティーを有するクルクミンのリン脂質複合体 Download PDFInfo
- Publication number
- JP5448462B2 JP5448462B2 JP2008557619A JP2008557619A JP5448462B2 JP 5448462 B2 JP5448462 B2 JP 5448462B2 JP 2008557619 A JP2008557619 A JP 2008557619A JP 2008557619 A JP2008557619 A JP 2008557619A JP 5448462 B2 JP5448462 B2 JP 5448462B2
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- phospholipid
- complex
- cancer
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims description 75
- 235000012754 curcumin Nutrition 0.000 title claims description 40
- 229940109262 curcumin Drugs 0.000 title claims description 40
- 239000004148 curcumin Substances 0.000 title claims description 40
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims description 40
- -1 Curcumin phospholipid Chemical class 0.000 title description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 244000163122 Curcuma domestica Species 0.000 claims description 9
- 235000003373 curcuma longa Nutrition 0.000 claims description 9
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 235000013976 turmeric Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 description 14
- 229930153442 Curcuminoid Natural products 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012627 chemopreventive agent Substances 0.000 description 2
- 229940124443 chemopreventive agent Drugs 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000001584 soft palate Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 description 1
- 229920002982 Procyanidin A2 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
粉砕し、乾燥したウコン根茎(1000g)を、エタノール−水 9:1の混合物(6680ml)で抽出した。得られる水アルコール溶液を減圧下で濃縮し、真空下60℃の乾燥器内で乾燥を完了させることによって、17.4%w/wのクルクミン含有量および29.2%w/wの総クルクミノイド含有量を有する、69.3gのオレンジ色ペーストを得た。
粉砕し、乾燥したウコン根茎(1000g)を、ヘキサン(2500ml)で脱脂した後、エタノール−水 95:5の混合物(7500ml)で抽出した。次いでこの水アルコール溶液にヘキサン(500ml)を徐々に加え、得られる混合物を24時間静置することによって、クルクミノイドを結晶化させた。微結晶性オレンジ色固体を濾過し、真空下60℃で乾燥させることによって、71.74%のクルクミン含有量および93.8%w/wの総クルクミノイド含有量を有する、36.7gの抽出物を得た。
実施例1からの20gの生成物を、エタノール(400ml)に溶解させ、この溶液を還流した。30gのダイズリン脂質を、還流下で攪拌しながら徐々に少しずつ加えた。得られる懸濁液を攪拌しながら1時間還流し、次いで減圧下で高温濃縮し、最後に乾燥器内で乾燥させた。7.54%のクルクミン含有量および12.1%w/wの総クルクミノイド含有量を有する、46.7gのオレンジ色蝋状生成物を得た。
93.8%w/wの総クルクミノイド含有量を有する、20gのウコン根茎抽出物を、エタノール(800ml)中に溶解させ、この溶液を還流した。80gのダイズリン脂質を、還流下で攪拌しながら徐々に少しずつ加えた。得られる懸濁液を、攪拌しながら1時間還流し、次いで減圧下で高温濃縮し、最後に乾燥器内で乾燥させた。13.2%のクルクミン含有量および16.9%w/wの総クルクミノイド含有量を有する、97.6gのオレンジ色蝋状生成物を得た。
試験を実施することによって、本発明のリン脂質複合体によって、および複合体を形成していないクルクミンを含有する抽出物によって提供されるクルクミンのバイオアベイラビリティーを比較した。
雄のウィスターラット(250g)を一晩絶食させ、実施例2によって得られた抽出物または実施例4によって得られた複合体のいずれかを、クルクミンに関して340mg/Kgの用量で、経口胃管栄養法によって投与した。
実施例4に記載した、リン脂質で複合体を形成したクルクミンの投与後の、親クルクミンについてのピーク血漿レベルおよび血漿濃度時間曲線下面積(AUC)は、実施例2の抽出物(複合体を形成していないクルクミン)での処置後に見られる、相当する値よりも5倍高かった(表1)。
結果は、本発明のクルクミンのリン脂質複合体は、複合体を形成していないクルクミンよりも、高い全身性レベルの親剤を提供することを示す。
1. Cheng AL, et al., Anticancer Res 21: 2895-2900.
2. Duvoix A, et al., Cancer Lett 223: 181-190.
3. Fagerholm U, et al., J Pharm Pharmacol 50: 467-443.
4. Garcea G, et al., Br J Cancer 90: 1011-1015.
5. Garcea G, et al., Cancer Epidemiol Biomarkers Prev 14: 120-125.
6. Goel A, et al., Cancer Letters 172: 111-118.
7. Ireson C, et al., Cancer Res 61: 1058-1064.
8. Ireson C, et al., Cancer Epidemiol. Biomarkers & Prev 11: 97-104.
9. Kawamori T, et al., Cancer Res 59: 597-601.
10. Kelloff GJ, et al., J Cell Biochem 63: 54-71.
11. Kuttan R, et al., Tumors 3: 29-31.
12. Li, L., et al., Cancer 104: 1322-1331.
13. Mourao SC, et al., Int J Pharmaceut 295: 157-162.
14. Plummer SM., et al., Oncogene 18: 6013-6020.
15. Rao CV, et al., Cancer Res 55: 259-266.
16. Shao Z-M, et al., Int J Cancer 98: 234-240.
17. Sharma RA, et al., Clin Cancer Res 10: 6847-6854.
18. Surh YJ Nature Rev Cancer 3: 768-780.
19. Workman P, et al., Brit J Cancer 77: 1-10.
Claims (8)
- クルクミンのリン脂質複合体であって、前記クルクミンに対する前記リン脂質の比が10から1w/wの範囲内である複合体。
- 前記リン脂質がダイズリン脂質である、請求項1に記載の複合体。
- 前記リン脂質が、ホスファチジルコリン、ホスファチジルセリン、ホスファチジルエタノールアミンから選択される、請求項2に記載の複合体。
- 前記クルクミンに対する前記リン脂質の比が5から1w/wである、請求項2に記載の複合体。
- 請求項1から3のいずれかに記載の複合体を調製するための方法であって、ウコン根茎の水アルコール抽出物を、アルコール溶媒中でリン脂質と反応させ、次いで濃縮し、乾燥させることによって前記複合体を単離する方法。
- 前記アルコール溶媒がエタノールである、請求項1に記載の方法。
- 適当な医薬担体と混合した、請求項1から4のいずれかに記載の複合体を活性成分として含有する医薬組成物。
- 癌予防薬の調製のための、請求項1から4のいずれかに記載の複合体の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06004820A EP1837030A1 (en) | 2006-03-09 | 2006-03-09 | Phospholipid complexes of curcumin having improved bioavailability |
EP06004820.4 | 2006-03-09 | ||
PCT/EP2007/001487 WO2007101551A2 (en) | 2006-03-09 | 2007-02-21 | Phospholipid complexes of curcumin having improved bioavailability |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009529506A JP2009529506A (ja) | 2009-08-20 |
JP2009529506A5 JP2009529506A5 (ja) | 2013-07-25 |
JP5448462B2 true JP5448462B2 (ja) | 2014-03-19 |
Family
ID=36677274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008557619A Active JP5448462B2 (ja) | 2006-03-09 | 2007-02-21 | 改善されたバイオアベイラビリティーを有するクルクミンのリン脂質複合体 |
Country Status (17)
Country | Link |
---|---|
US (2) | US10603329B2 (ja) |
EP (2) | EP1837030A1 (ja) |
JP (1) | JP5448462B2 (ja) |
KR (1) | KR101423269B1 (ja) |
CN (1) | CN101400360A (ja) |
AU (1) | AU2007222667B2 (ja) |
CA (1) | CA2644017C (ja) |
DK (1) | DK1991244T3 (ja) |
ES (1) | ES2757580T3 (ja) |
HU (1) | HUE046597T2 (ja) |
IL (1) | IL193966A (ja) |
NO (1) | NO344242B1 (ja) |
PL (1) | PL1991244T3 (ja) |
PT (1) | PT1991244T (ja) |
RU (1) | RU2450818C2 (ja) |
SI (1) | SI1991244T1 (ja) |
WO (1) | WO2007101551A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9192644B2 (en) * | 2006-03-06 | 2015-11-24 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders |
WO2009080850A1 (es) | 2007-12-21 | 2009-07-02 | Asac Compañia De Biotecnologia E Investigacion, S.A. | Método para aumentar la eficacia terapéutica de los curcuminoides y análogos. |
US9700525B2 (en) | 2008-08-20 | 2017-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College | Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders |
WO2010023128A1 (en) * | 2008-08-29 | 2010-03-04 | Chr. Hansen A/S | Turmeric curcumin compositions with low residual solvent |
IT1395086B1 (it) * | 2009-03-11 | 2012-09-05 | Velleja Res Srl | Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante |
SI2229940T1 (sl) | 2009-03-20 | 2016-01-29 | Bioxtract S.A. | Farmacevtski sestavek s protivnetnimi in antihistaminskimi lastnostmi |
ES2604127T3 (es) | 2009-03-20 | 2017-03-03 | Bioxtract S.A. | Composición farmacéutica que presenta propiedades antiinflamatorias |
IT1395351B1 (it) | 2009-07-09 | 2012-09-14 | Axioma Srl | Formulazioni orali ad elevata biodisponibilita' orale costituite da miscele di frazioni lipofile e idrofile ottenute a partire dalla propoli |
WO2011082290A2 (en) | 2009-12-31 | 2011-07-07 | Organomed Corporation | Formulations from natural products, turmeric, and aspirin |
CN102068419A (zh) * | 2010-12-28 | 2011-05-25 | 神威药业有限公司 | 一种姜黄素组合物 |
US8785380B2 (en) | 2011-02-01 | 2014-07-22 | M/S Akay Flavours & Aromatics Pvt Ltd. | Formulation containing curcuminoids exhibiting enhanced bioavailability |
KR20150064234A (ko) | 2011-05-16 | 2015-06-10 | 옴니액티브 헬스 테크놀로지스 리미티드 | 증가된 생체이용률을 갖는 커큐민을 포함하는 수용성 조성물 및 이의 방법 |
ITTO20110901A1 (it) * | 2011-10-10 | 2013-04-11 | Medestea Biotech S P A | Composizione sinergica per la prevenzione ed il trattamento di disturbi connessi all'invecchiamento |
ITPD20120021A1 (it) * | 2012-01-26 | 2013-07-27 | Fidia Farmaceutici | "nuove composizioni farmaceutiche contenenti fosfatidilserina e curcumina". |
US20150110866A1 (en) * | 2012-05-22 | 2015-04-23 | Harold Gordon Cave | Complexes and compositions containing curcumin |
EP2852395A4 (en) * | 2012-05-22 | 2015-12-16 | Harold Gordon Cave | IMPROVED COMPLEXES AND COMPOSITIONS WITH CURRICULUM |
CN103120798A (zh) * | 2013-01-10 | 2013-05-29 | 施冬云 | 一种具有抗氧化应激作用的磷脂复合物制备方法及其应用 |
US20160000714A1 (en) | 2013-03-06 | 2016-01-07 | Capsugel Belgium Nv | Curcumin solid lipid particles and methods for their preparation and use |
EP2996704B1 (en) * | 2013-05-14 | 2021-01-06 | Mars, Incorporated | Joint care composition |
RU2677894C2 (ru) * | 2014-02-20 | 2019-01-22 | Индена С.П.А. | Композиции, содержащие экстракты Curcuma Longa и Echinacea angustifolia, которые являются полезными для уменьшения периферического воспаления и боли |
RU2571270C1 (ru) * | 2014-07-17 | 2015-12-20 | Открытое Акционерное Общество "Фаберлик" | Липосомальное наносредство на основе продуктов, полученных из корневищ куркумы |
CA2963942A1 (en) * | 2014-10-08 | 2016-04-14 | Boston Biopharm, Inc. | Compositions and methods for increasing the bioavailability of one or more compounds |
EP3218006A4 (en) * | 2014-11-11 | 2018-08-15 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
WO2016087261A1 (en) | 2014-12-04 | 2016-06-09 | Capsugel Belgium N.V. | Lipid multiparticulate formulations |
EP3150214A1 (en) * | 2015-10-01 | 2017-04-05 | INDENA S.p.A. | Compositions containing extracts of curcuma spp and zingiber officinale which are useful to reduce peripheral inflammation and pain |
WO2017095138A1 (en) * | 2015-11-30 | 2017-06-08 | Gil Medical Center | Curcumin-containing lipid nanoparticle complex comprising ginsenosides |
CN108366974A (zh) * | 2015-12-16 | 2018-08-03 | 维韦克·阿南德·帕拉库尔 | 天然化合物的三分子复合物 |
CN105999290B (zh) * | 2016-04-21 | 2019-04-09 | 中国人民解放军第四军医大学 | 一种磷脂酰丝氨酸修饰的姜黄素纳米粒 |
WO2018003857A1 (ja) * | 2016-06-29 | 2018-01-04 | 株式会社セラバイオファーマ | 非経口投与用医薬組成物 |
US20170172921A1 (en) * | 2016-12-14 | 2017-06-22 | Mahmoud Reza Jaafari | Polyphenolic compounds encapsualated in long circulating liposomes and use thereof |
KR101948407B1 (ko) | 2017-01-20 | 2019-02-14 | 가천대학교 산학협력단 | 커큐민이 포집된 진세노사이드 및 인지질 기반 지질나노입자를 유효성분으로 함유하는 헬리코박터 파이로리 감염의 예방 또는 치료용 조성물 |
CN107213467A (zh) * | 2017-05-22 | 2017-09-29 | 江苏大学 | 一种姜黄素磷脂复合物的制备方法 |
RU2684111C1 (ru) * | 2018-02-07 | 2019-04-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Способ получения лекарственного средства с метионином и экстрактом куркумы в виде гранул с кишечнорастворимым покрытием системного действия |
BE1026393B1 (fr) * | 2018-06-18 | 2020-01-28 | Normaphar | Composition pour utilisation dans le traitement de l'ostéopénie et/ou de l'ostéoporose |
FR3082425B1 (fr) * | 2018-06-18 | 2020-09-11 | Normaphar | Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose |
CN109846865B (zh) * | 2018-12-26 | 2022-03-25 | 晨光生物科技集团股份有限公司 | 一种姜黄素制剂及其制备方法 |
CN109589410B (zh) * | 2018-12-26 | 2022-02-01 | 晨光生物科技集团股份有限公司 | 一种姜黄素制剂及其制备方法 |
IT201900003907A1 (it) | 2019-03-18 | 2020-09-18 | Indena Spa | Composizioni comprendenti curcumina e coenzima q10 |
CN111803632B (zh) | 2019-04-09 | 2022-04-29 | 北京五和博澳药业股份有限公司 | 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途 |
GB202011069D0 (en) | 2020-07-17 | 2020-09-02 | Univ Of Lincoln | New curcumin products and uses |
KR20220086467A (ko) | 2020-12-16 | 2022-06-23 | 가톨릭대학교 산학협력단 | 다당류를 이용하여 커큐민의 안정성 및 생체 이용률이 향상된 나노복합체 및 이의 제조방법 |
KR20220086018A (ko) | 2020-12-16 | 2022-06-23 | 가톨릭대학교 산학협력단 | 셀룰로오스를 이용하여 커큐민의 안정성 및 생체 이용률이 향상된 나노복합체 및 이의 제조방법 |
EP4289287A1 (en) | 2021-09-28 | 2023-12-13 | Binotec Co., Ltd. | Curcumin nanoparticle complex having modified particle surface and method for preparing same |
JP7321229B2 (ja) * | 2021-10-20 | 2023-08-04 | 義美食品股▲ふん▼有限公司 | ウコン根茎からクルクミノイドを分離する方法 |
CN114557965B (zh) * | 2022-02-09 | 2023-06-09 | 汕头大学 | 一种提高姜黄素稳定性和生物可及性的磷脂复合物纳米粒及制备方法 |
WO2024032507A1 (zh) * | 2022-08-09 | 2024-02-15 | 湖南健瑞医药科技有限公司 | 金属-磷脂复合物、金属-磷脂复合物颗粒和药物-脂质颗粒及其制备方法与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1215291B (it) | 1985-07-17 | 1990-01-31 | Inverni Della Beffa Spa | Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche. |
IT1201149B (it) | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
IT1203515B (it) | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
IT1296920B1 (it) | 1997-12-04 | 1999-08-03 | Indena Spa | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
IT1304183B1 (it) | 1998-12-18 | 2001-03-08 | Indena Spa | Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici. |
CA2536738A1 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
CN1283237C (zh) | 2004-11-22 | 2006-11-08 | 山东大学 | 姜黄素磷脂复合物及其制备方法 |
-
2006
- 2006-03-09 EP EP06004820A patent/EP1837030A1/en not_active Withdrawn
-
2007
- 2007-02-21 JP JP2008557619A patent/JP5448462B2/ja active Active
- 2007-02-21 EP EP07703532.7A patent/EP1991244B1/en active Active
- 2007-02-21 SI SI200732132T patent/SI1991244T1/sl unknown
- 2007-02-21 CA CA2644017A patent/CA2644017C/en active Active
- 2007-02-21 HU HUE07703532A patent/HUE046597T2/hu unknown
- 2007-02-21 CN CNA2007800082936A patent/CN101400360A/zh active Pending
- 2007-02-21 PT PT77035327T patent/PT1991244T/pt unknown
- 2007-02-21 ES ES07703532T patent/ES2757580T3/es active Active
- 2007-02-21 WO PCT/EP2007/001487 patent/WO2007101551A2/en active Application Filing
- 2007-02-21 US US12/281,994 patent/US10603329B2/en active Active
- 2007-02-21 PL PL07703532T patent/PL1991244T3/pl unknown
- 2007-02-21 RU RU2008136189/15A patent/RU2450818C2/ru active
- 2007-02-21 KR KR1020087021905A patent/KR101423269B1/ko active IP Right Grant
- 2007-02-21 DK DK07703532T patent/DK1991244T3/da active
- 2007-02-21 AU AU2007222667A patent/AU2007222667B2/en active Active
-
2008
- 2008-09-08 NO NO20083850A patent/NO344242B1/no unknown
- 2008-09-08 IL IL193966A patent/IL193966A/en active IP Right Grant
-
2019
- 2019-02-13 US US16/274,623 patent/US20190175628A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007101551A2 (en) | 2007-09-13 |
EP1837030A1 (en) | 2007-09-26 |
IL193966A (en) | 2015-01-29 |
IL193966A0 (en) | 2011-08-01 |
WO2007101551A3 (en) | 2007-10-25 |
PL1991244T3 (pl) | 2020-03-31 |
KR20080112224A (ko) | 2008-12-24 |
KR101423269B1 (ko) | 2014-07-25 |
ES2757580T3 (es) | 2020-04-29 |
US20090131373A1 (en) | 2009-05-21 |
US10603329B2 (en) | 2020-03-31 |
EP1991244B1 (en) | 2019-10-02 |
US20190175628A1 (en) | 2019-06-13 |
CA2644017C (en) | 2019-07-30 |
SI1991244T1 (sl) | 2019-11-29 |
RU2008136189A (ru) | 2010-03-20 |
NO20083850L (no) | 2008-12-03 |
DK1991244T3 (da) | 2019-11-18 |
HUE046597T2 (hu) | 2020-03-30 |
EP1991244A2 (en) | 2008-11-19 |
NO344242B1 (no) | 2019-10-14 |
PT1991244T (pt) | 2019-11-29 |
AU2007222667A1 (en) | 2007-09-13 |
JP2009529506A (ja) | 2009-08-20 |
RU2450818C2 (ru) | 2012-05-20 |
AU2007222667B2 (en) | 2012-11-08 |
CA2644017A1 (en) | 2007-09-13 |
CN101400360A (zh) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5448462B2 (ja) | 改善されたバイオアベイラビリティーを有するクルクミンのリン脂質複合体 | |
US10512616B2 (en) | Composition to enhance the bioavailability of curcumin | |
US10485843B2 (en) | Composition to enhance the bioavailability of curcumin | |
DK170804B1 (da) | Komplekser af en eller flere flavanolignaner med et eller flere phospholipider, fremgangsmåde til fremstilling af komplekserne samt farmaceutiske midler indeholdende komplekserne | |
JP2009529506A5 (ja) | ||
JP2009533365A (ja) | 改善されたバイオアベイラビリティを有するオリーブの果実又は葉の抽出物のリン脂質複合体 | |
CN113573722A (zh) | 包含姜黄素和辅酶q10的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130610 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130610 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5448462 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |